Prioritizing the human genome: Knowledge management for drug discovery

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 3, 2003, Pages 310-316

  Golden, James B ^a  

^a 454 Corporation   (United States)

Author keywords

Bioinformatics; Drug discovery; Knowledge management; Knowledge representation; Target validation

Indexed keywords

BIOLOGICAL MARKER; GENE PRODUCT;

BIOINFORMATICS; DATA ANALYSIS; DATA BASE; DRUG INFORMATION; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN GENOME; ORGANIZATION; REVIEW;

ANIMALS; DATABASE MANAGEMENT SYSTEMS; DRUG DELIVERY SYSTEMS; GENOME, HUMAN; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038458880     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R et al: Initial sequencing and analysis of the human genome. Nature (2001) 409:860-921. This article describes the results of the public Human Genome Project.
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD et al: The sequence of the human genome. Science (2001) 291:1304-1351. This article describes the results of the private (Celera Genomics) Human Genome Project.
3. Grenet O: Significance of the human genome sequence to drug discovery. Pharmacogenomics J (2001) 1:11-12.
4. Guttmacher AE, Collins FS: Genomic medicine - A primer. N Engl J Med (2002) 347:1512-1520. An excellent overview of the Human Genome Project and its potential impact on medicine. This article was authored for physicians, and gives several good examples of how genomic medicine might be realized in the clinical setting.
5. Pederson T: A century of DNA reaches the bedside. Pharos Alpha Omega Alpha Honor Med Soc (2002) 65:27-32.
6. Rosamond J, Allsop A: Harnessing the power of the genome in the search for new antibiotics. Science (2000) 287:1973-1976.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344:783-792. This paper details a clinical study wherein patients with metastatic breast cancer are treated with a monoclonal antibody that targets a specific growth factor receptor gene, HER2.
8. Capdeville R, Buchdunger E, Zimmermann J, Matter A: GLIVEC (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Disc (2002) 1:493-502. A review article discussing the first selective tyrosine kinase inhibitor approved for the treatment of cancer. Glivec (or Gleevec) is one example of how the promise of genomic medicine might be realized.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M et al: A gene-expression signature as a predictor of survival In breast cancer. N Engl J Med (2002) 347:1999-2009. This paper presents a comprehensive study of gene expression across a large patient population. While the study presents a prognostic indicator, it clearly demonstrates how genomics might be used for diagnostic medicine to recommend treatment protocols.
10. Herrera S: Knowledge Is power; but pills are profits. Red Herring (May 2002). http://www.redherring.com/insider/2002/0502/2727.html
11. Stipp D: The next frontier: Can personalized drugs pay off? Fortune (April 2002). http://www.fortune.com/fortune/investing/articles/0, 15114,369205,00.html
12. Navigating the evolving world of drug discovery. Nat Rev Drug Disc (2002) 1:3.
13. Horrobin DF: Realism In drug discovery - Could Cassandra be right? Nat Biotechnol (2001) 19:1099-1100.
14. Drews J: Drug discovery: A historical perspective. Science (2000) 287:1960-1964. A historical review of the drug discovery process from the work of 19th Century German chemists through to the Human Genome Project.
15. Drews J, Ryser S: Classic drug targets. Nat Biotechnol (1997) 15. http://www.biomedicine.ch/publications/biomed/poster.html A pullout poster source of an often-quoted statistic on the number of human genomic targets for all FDA approved medicines (as of 1996). Recent work has shown that this number could be out by a factor of two [personal communication with Pena and Burgess].
16. Aparicio SA: How to count-human genes. Nat Genet (2000) 25:129-130. An excellent short review of papers estimating the number of genes in the human genome prior to completion of the draft sequence. Many of the issues presented are significant to determine what constitutes a gene, and how those genes may be found in the completed (draft) genome.
17. Hogenesch JB, Ching KA, Batalov S, Su Al, Walker JR, Zhou Y, Kay SA, Schultz PG, Cooke MP: A comparison of the Celera and Ensembl predicted gene sets reveals little overlap in novel genes. Cell (2001) 106:413-415. A comparison of the sets of predicted genes from both public and private Human Genome Projects.
18. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Disc (2002) 1:727-730. An important paper describing Pfizer's attempt to prioritize the human genome into a (limited) number of targets to improve the probability of discovering successful drugs.
19. Zambrowicz BP, Sands AT: Knockouts model the 100 best-selling drugs - Will they model the next 100? Nat Rev Drug Disc (2003) 2:38-51. An interesting perspective on a reverse genetic method to find a prioritized set of targets with the goal of creating blockbuster drugs.
20. Myers S, Baker A: Drug-discovery: An operating model for a new era. Nat Biotechnol (2001) 19:727-730.
21. Knowles J, Gromo G: A guide to drug discovery: Target selection in drug discovery. Nat Rev Drug Disc (2003) 2:63-69.
22. Kahn S: Bioinformatics. A holistic approach to drug discovery. Drug Disc Today (2002) 7:633-634.
23. Saviotti PP, deLooze MA, Michelland S, Catherine D: The changing marketplace of bioinformatics. Nat Biotechnol (2000) 18:1247-1249.
24. Seemann P: A prescription for knowledge management: What Hoffmann-La Roche's case can teach others. Perspectives on Business Innovation. Managing Organizational Knowledge. The Cap Gemini Ernst & Young Center for Business Innovation, Cambridge, MA, USA (1996) (1):26-33. http://www.cbi.cgey.com/journal/issuel/features/apresc/index.html An excellent review of Hoffmann-La Roche's approach to knowledge management. This article clearly demonstrates that an actual product of the discovery effort is the IND itself.
25. Macintosh A: Position paper on knowledge asset management. Artificial Intelligence Applications Institute, University of Edinburgh, UK. http://www.aiai.ed.ac.uk/
26. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Rapp BA, Wheeler DL: GenBank. Nucleic Acids Res (2002) 30:17-20.
27. Wheeler DL, Church DM, Lash AE, Leipe DD, Madden TL, Pontius JU, Schuler GD, Schriml LM, Tatusova TA, Wagner L, Rapp BA et al: Database resources of the National Center for Biotechnology Information: 2002 update. Nucleic Acids Res (2002) 30:3-16.
28. Tatusov RL, Natale DA, Garkavtsev IV, Tatusova TA, Shankavaram UT, Rao BS, Kiryutin B, Galperin MY, Fedorova ND, Koonin EV: The COG database: New developments In phylogenetic classification of proteins from complete genomes. Nucleic Acids Res (2001) 29:22-28.
29. Wolfsberg TG, Wetterstrand KA, Guyer MS, Collins FS, Baxevanis AD: A user's guide to the human genome. Nat Genet (2002) 32(Suppl):1-79. A good introduction to the public tools available for analyzing the sequence from the public Human Genome Project.
30. Mathe C, Sagot MF, Schiex T, Rouze P: Current methods of gene prediction, their strengths and weaknesses. Nucleic Acids Res (2002) 30:4103-4117.
31. Rust AG, Mongin E, Birney E: Genome annotation techniques: New approaches and challenges. Drug Disc Today (2002) 7:S70-S76.
32. Duckworth DM, Sanseau P: In silico Identification of novel therapeutic targets. Drug Disc Today (2002) 7:S64-S69.
33. Blake J, Ashburner M, Ball CA, Blake JA, Butler H, Cherry JM, Corradi J, Dolinski K, Eppig JT, Harris M, Hill DP et al: Creating the gene ontology resource: Design and Implementation. Genome Res (2001) 11:1425-1433. An introduction to the Gene Ontology (GO) project.
34. Hill DP, Blake JA, Richardson JE, Ringwald M: Extension and integration of the gene ontology (GO): Combining GO vocabularies with external vocabularies. Genome Res (2002) 12:1982-1991.
35. Perez-Iratxeta C, Bork P, Andrade MA: Association of genes to genetically Inherited diseases using data mining. Nat Genet (2002) 31:316-319.
36. Neumann E, Thomas J: Knowledge assembly for the life sciences. Drug Disc Today (2002) 7:S160-S162.
37. Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW: A bioinformatics-based strategy Identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. Genome Res (2002) 12:969-975.
38. Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ: Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res (2000) 10:1393-1402. An example of how to find novel genes in public databases, and to qualify those genes using genomic techniques.
39. Saha S, Sparks AB, Rago C, Akmaev V, Wang CJ, Vogelstein B, Kinzler KW, Velculescu VE: Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 20:508-512. A description of LongSAGE (high-throughput expression) to identify and qualify novel genes in the human genome.
40. Thomas SM: Genomics and intellectual property rights. Drug Disc Today (1999) 4:134-138.
41. Ilag LL, Ng JH, Beste G, Henning SW: Emerging high-throughput drug target validation technologies. Drug Disc Today (2002) 7:S136-S142.
42. Branca MA, Bolte BM: Accelerating target validation, part 1: Assembling the technology platform. Spectrum Life Sciences (2002): Report 02H503.
43. Branca MA: Accelerating target validation, part II: Speeding analysis using cellular assays and other high-throughput technologies. Spectrum Life Sciences (2002):Report 02H507.
44. Baker D, Sali A: Protein structure prediction and structural genomics. Science (2001) 294:93-96.
45. Cristobal S, Zemla A, Fischer D, Rychlewski L, Elofsson A: A study of quality measures for protein threading models. BMC Bioinformatics (2001) 2:5.
46. Maggio ET, Ramnarayan K: Recent developments In computational proteomics. Drug Disc Today (2001) 6:996-1004.
47. Stevens RC, Yokoyama S, Wilson IA: Global efforts in structural genomics. Science (2001) 294:89-92.
48. Schreiber SL: Target-oriented and diversily-oriented organic synthesis In drug discovery. Science (2000) 287:1964-1969. A seminal paper introducing the concept of 'chemical genomics', a method to synthesize small molecules capable of perturbing any disease-related pathway.
49. Zanders ED, Bailey DS, Dean PM: Probes for chemical genomics by design. Drug Disc Today (2002) 7:711-718.
50. Agrafiotis DK, Lobanov VS, Salemme FR: Combinatorial Informatics In the post-genomics ERA. Nat Rev Drug Disc (2002) 1:337-346.
51. Bajorath J: Rational drug discovery revisited: Interfacing experimental programs with blo- and chemo-informatics. Drug Disc Today (2002) 6:989-995.
52. Joseph-McCarthy D: An overview of In silico design and screening: Toward efficient drug discovery. Curr Drug Disc (2002) March:20-23.
53. Miller MA: Chemical database techniques In drug discovery. Nat Rev Drug Disc (2002) 1:220-227.
54. Sheridan RP, Kearsley SK: Why do we need so many chemical similarity search methods? Drug Disc Today (2002) 7:903-911.
55. Wang Y, Anderson JB, Chen J, Geer LY, He S, Hurwitz DI, Liebert CA, Madej T, Marchler GH, Marchler-Bauer A, Panchenko AR et al: MMDB: Entrez's 3D-structure database. Nucleic Acids Res (2002) 30:249-252.
56. Bajorath J: Virtual screening in drug discovery: Methods, expectations and reality. Curr Drug Disc (2002) March:24-28.
57. Hemmila IA, Hurskainen P: Novel detection strategies for drug discovery. Drug Disc Today (2002) 7: S150-S156.
58. Waszkowycz B, Perkins TD, Sykes RA, Li J: Large-scale virtual screening for discovering leads in the postgenomic era. IBM Systems (2001) 40:360-376.
59. Ginsburg GS, McCarthy JJ: Personalized medicine: Revolutionizing drug discovery and patient care. A TRENDS Guide to Genetic and Genomic Medicine (2002):S48-S54.
60. Roses AD: Genome-based pharmacogenetics and the pharmaceutical Industry. Nat Rev Drug Disc (2002) 1:541-549.
61. Butina D, Segall MD, Frankcombe K: Predicting ADME properties in silico: Methods and models. Drug Disc Today (2002) 7:S83-S88.
62. Castle AL, Carver MP, Mendrick DL: Toxicogenomics: A new revolution In drug safety. Drug Disc Today (2002) 7:728-736.
63. Lindpainter K: The Impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Disc (2002) 1:463-469. An excellent review article on pharmacogenetics and pharmacogenomics with clear definitions and vocabulary delineating the two areas of research.
64. Liebman MN: Biomedical informatics: The future for drug development. Drug Disc Today (2002) 7:S197-S203.
65. Hodgson J: The headache of knowledge management. Nat Biotechnol (2001) 19(Suppl):BE44-BE46.